GlobeNewswire: Health Contains the last 10 of 77186 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:07:44ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/29/2854741/0/en/The-Global-Nutraceutical-Excipients-Market-in-the-Age-of-Diverse-Therapeutic-Applications.html?f=22&fvtc=1&fvtv=HealthThe Global Nutraceutical Excipients Market in the Age of Diverse Therapeutic Applications2024-03-29T13:30:00Z<![CDATA[Nutraceutical Excipients Market Booming: Set to Reach $6.1 Billion by 2028! Are you in the nutraceutical industry? This is a must-read for you! Nutraceutical Excipients Market Booming: Set to Reach $6.1 Billion by 2028! Are you in the nutraceutical industry? This is a must-read for you!]]>https://www.globenewswire.com/news-release/2024/03/29/2854736/0/en/Live-Well-Fully-Launch-Pioneering-Love-Another-Way-Philosophy-to-Help-Women-with-an-Adult-Son-or-Daughter-Dealing-with-an-Addiction-or-Mental-Illness.html?f=22&fvtc=1&fvtv=HealthLive Well & Fully Launch Pioneering ‘Love Another Way’ Philosophy to Help Women with an Adult Son or Daughter Dealing with an Addiction or Mental Illness2024-03-29T13:00:00Z<![CDATA[Orefield, PA, March 29, 2024 (GLOBE NEWSWIRE) -- Live Well & Fully, one of the only organizations in the USA and Canada that offers programs tailored specifically for moms whose adult children are struggling with addiction or mental health issues, is proud to announce the launch of its pioneering ‘Love Another Way’ philosophy to family healing and Decision making in recovery.]]>https://www.globenewswire.com/news-release/2024/03/29/2854723/0/en/Pharmaceutical-Membrane-Filtration-Market-is-Expected-to-Reach-19-6-billion-MarketsandMarkets.html?f=22&fvtc=1&fvtv=HealthPharmaceutical Membrane Filtration Market is Expected to Reach $19.6 billion | MarketsandMarkets™2024-03-29T12:30:00Z<![CDATA[Chicago, March 29, 2024 (GLOBE NEWSWIRE) -- Pharmaceutical Membrane Filtration market in terms of revenue was estimated to be worth $10.6 billion in 2024 and is poised to reach $19.6 billion by 2029, growing at a CAGR of 13.1% from 2024 to 2029 according to a latest report published by MarketsandMarkets™. Stringent regulatory requirements, increasing number of R&D investments made by top pharmaceutical companies, increased preference of biopharmaceutical manufacturers and researchers for using single use technologies, are some factors responsible for the growth of the market. On the other hand, issues such as fouling of membrane, and the high capital investment required to set up new production facilities may limit the entry of small players into the market, thereby hampering the market growth.]]>https://www.globenewswire.com/news-release/2024/03/28/2854508/0/en/Zevra-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Updates.html?f=22&fvtc=1&fvtv=HealthZevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates2024-03-28T20:32:04Z<![CDATA[Launch of OLPRUVA® underway]]>https://www.globenewswire.com/news-release/2024/03/28/2854501/0/en/Applied-Therapeutics-Provides-FDA-Update-on-PDUFA-Target-Action-Date-for-Govorestat-for-the-Treatment-of-Classic-Galactosemia.html?f=22&fvtc=1&fvtv=HealthApplied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia2024-03-28T20:30:00Z<![CDATA[NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia by three months. The FDA has set a new Prescription Drug User Fee Act (PDUFA) target action date of November 28, 2024.]]>https://www.globenewswire.com/news-release/2024/03/28/2854497/0/en/Centessa-Pharmaceuticals-Reports-Business-Highlights-and-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2023.html?f=22&fvtc=1&fvtv=HealthCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 20232024-03-28T20:28:47Z<![CDATA[BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/03/28/2854466/0/en/Candel-Therapeutics-Announces-Oral-Presentation-During-the-5th-Glioblastoma-Drug-Development-Summit-with-Update-on-Phase-1b-Clinical-Trial-of-CAN-3110-in-Recurrent-High-Grade-Gliom.html?f=22&fvtc=1&fvtv=HealthCandel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma2024-03-28T20:05:00Z<![CDATA[NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the presentation of updated data from an ongoing phase 1b clinical trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with rHGG that has recurred after standard of care (SoC) treatment. The data were presented today during the 5th Glioblastoma Drug Development Summit in Boston, Massachusetts.]]>https://www.globenewswire.com/news-release/2024/03/28/2854471/0/en/Absci-to-Participate-in-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html?f=22&fvtc=1&fvtv=HealthAbsci to Participate in the 23rd Annual Needham Virtual Healthcare Conference2024-03-28T20:05:00Z<![CDATA[VANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference.]]>https://www.globenewswire.com/news-release/2024/03/28/2854446/0/en/Achieve-Life-Sciences-Reports-Financial-Results-for-Fourth-Quarter-and-Year-End-2023-and-Provides-Corporate-Update.html?f=22&fvtc=1&fvtv=HealthAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update2024-03-28T20:01:21Z<![CDATA[Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024 Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024]]>https://www.globenewswire.com/news-release/2024/03/28/2854443/0/en/Spectral-Medical-Announces-Fourth-Quarter-and-Fiscal-2023-Results-and-Provides-Corporate-Update.html?f=22&fvtc=1&fvtv=HealthSpectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update2024-03-28T20:00:58Z<![CDATA[97 patients enrolled 97 patients enrolled ]]>